Rebound Effect Associated with JAK Inhibitor Use in the Treatment of Alopecia Areata

    December 2018 in “ Journal of the European Academy of Dermatology and Venereology ”
    Samantha Gordon, Minawaer Abudu, Pedro Zancanaro … David Rosmarin
    Studysummary This article is a Letter to the Editor discussing rebound effects associated with JAK inhibitor use in treating alopecia areata and reports no new clinical results.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on onlinelibrary.wiley.com →
    Discuss this study in the Community →

    Research cited in this study 6

    1. Excellent Response to Tofacitinib Treatment in a Patient with Alopecia Universalis Acta dermatovenerologica Alpina, Pannonica et Adriatica (Tiskana izd.) · 2017
    2. Oral Ruxolitinib Induces Hair Regrowth in Patients with Moderate-to-Severe Alopecia Areata JCI insight · 2016
    3. Alopecia Areata: Animal Models Illuminate Autoimmune Pathogenesis and Novel Immunotherapeutic Strategies Autoimmunity reviews · 2016
    4. Pharmacologic Inhibition of JAK-STAT Signaling Promotes Hair Growth Science Advances · 2015
    5. Organ-Level Quorum Sensing Directs Regeneration in Hair Stem Cell Populations Cell · 2015
    6. Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition Nature medicine · 2014

    Related research 3

    1. Twenty Nail Dystrophy with Alopecia Areata in an Atopic Child International journal of research in dermatology · 2019
    2. Oral Tofacitinib: A Promising Treatment in Atopic Dermatitis, Alopecia Areata, and Vitiligo Clinical and Experimental Dermatology · 2017
    3. Vitiligo After Diphencyprone for Alopecia Areata Dermatology Research and Practice · 2010